Nrl knockdown by AAV-delivered CRISPR/Cas9 prevents retinal degeneration in mice
Open accessThe DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Abstract
In retinitis pigmentosa, loss of cone photoreceptors leads to blindness, and preservation of cone function is a major therapeutic goal. However, cone loss is thought to occur as a secondary event resulting from degeneration of rod photoreceptors. Here we report a genome editing approach in which adeno-associated virus (AAV)-mediated CRISPR/Cas9 delivery to postmitotic photoreceptors is used to target the Nrl gene, encoding for Neural retina-specific leucine zipper protein, a rod fate determinant during photoreceptor development. Following Nrl disruption, rods gain partial features of cones and present with improved survival in the presence of mutations in rod-specific genes, consequently preventing secondary cone degeneration. In three different mouse models of retinal degeneration, the treatment substantially improves rod survival and preserves cone function. Our data suggest that CRISPR/Cas9-mediated NRL disruption in rods may be a promising treatment option for patients with retinitis pigmentosa.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A dual rAAVs system (rAAV.RKp.SpCas9; rAAV.U7.gRNA-Nrl) rescued vision in three mouse lines of rod retinal degeneration (Crx-Nrl -/-; rd10 or Pde6b -/-; Rho -/-) by knocking out Nrl in one or both alleles [219].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [219]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In recent years, viral vectors have been extensively applied to deliver CRISPR cassettes in vitro and in vivo largely owing to their high efficiency in gene delivery and long-term stable transgene expression [34, 58, 65].”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [58]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIH Image to ImageJ: 25 years of image analysis
Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012) · Nature Methods · doi:10.1038/nmeth.2089 · Cited by 64,638 · cited 1×
“47) 64 .”
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
BEDTools: a flexible suite of utilities for comparing genomic features
Quinlan, A. R., & Hall, I. M. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq033 · Cited by 27,437
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762 · cited 2×
“In contrast, the CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 gene editing system can efficiently disrupt genes at desired loci, enabling complete gene KO 17 .”
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234 · cited 1×
“Five sequences with leading scores and three that were previously reported 23,24 (ET1 to ET8, see Supplementary Table 1 and Supplementary Fig.”
GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists
Eden, E., Navon, R., Steinfeld, I., Lipson, D., & Yakhini, Z. (2009) · BMC Bioinformatics · doi:10.1186/1471-2105-10-48 · Cited by 3,356
Human photoreceptor topography
Curcio, C. A., Sloan, K. R., Kalina, R. E., & Hendrickson, A. E. (1990) · Journal of Comparative Neurology · doi:10.1002/cne.902920402 · Cited by 3,167 · cited 1×
“Rods are dim-light-sensing neurons distributed throughout the retina with the highest densities just outside of the macula 2,4 , whereas cones respond to higher levels of light and mediate colour vision.”
Cited by
Items 101–200 of 282
Comparison of CRISPR/Cas Endonucleases for in vivo Retinal Gene Editing
Li, F., Wing, K., Wang, J.-H., Luu, C. D., Bender, J. A., Chen, J., Wang, Q., Lu, Q., Nguyen Tran, M. T., Young, K. M., et al. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.570917 · Cited by 34
“2 (Bakondi et al., 2016; Hung et al., 2016; Latella et al., 2016; Huang et al., 2017; Jain et al., 2017; Ruan et al., 2017; Yu et al., 2017; Tsai et al., 2018; Li et al., 2019) SaCas9 Staphylococcus aureus NNGRRT ~3.”
BackgroundLohia, A., Sahel, D. K., Salman, M., Singh, V., Mariappan, I., Mittal, A., & Chitkara, D. (2022) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2022.02.001 · Cited by 33
“[87] Yu W , Mookherjee S , Chaitankar V , Hiriyanna S , Kim JW , Brooks M , et al.”
BackgroundNext generation therapeutics for retinal neurodegenerative diseases
Appell, M. B., Pejavar, J., Pasupathy, A., Rompicharla, S. V. K., Abbasi, S., Malmberg, K., Kolodziejski, P., & Ensign, L. M. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.063 · Cited by 34
CRISPR Interference–Potential Application in Retinal Disease
Peddle, C. F., Fry, L. E., McClements, M. E., & MacLaren, R. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072329 · Cited by 34
“Even partial reduction in the expression of toxic genes may slow the rate of degeneration and result in preservation of visual function and delay of vision loss [53,55,63,64].”
BackgroundCRISPR-Cas9 for treating hereditary diseases
Mani, I. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.01.017 · Cited by 41
Xie, S., Han, S., Qu, Z., Liu, F., Li, J., Yu, S., Reilly, J., Tu, J., Liu, X., Lu, Z., et al. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.01.022 · Cited by 33
Germline CRISPR/Cas9-Mediated Gene Editing Prevents Vision Loss in a Novel Mouse Model of Aniridia
Mohanna, S. Z. M., Hickmott, J. W., Lam, S. L., Chiu, N. Y., Lengyell, T. C., Tam, B. M., Moritz, O. L., & Simpson, E. M. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.03.002 · Cited by 34
In Vivo Applications of CRISPR-Based Genome Editing in the Retina
Yu, W., & Wu, Z. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00053 · Cited by 33
“Although persistent expression of CRISPR components did not cause obvious tissue damage in previous studies including our own (Platt et al., 2014; Yu et al., 2017), cellular and humoral immune responses in mice evoked by AAV-delivered Cas9 following intramuscular administration have indeed been…”
BackgroundMethodSelf-citationNakamura, P. A., Shimchuk, A. A., Tang, S., Wang, Z., DeGolier, K., Ding, S., & Reh, T. A. (2017) · eLife · doi:10.7554/elife.30577 · Cited by 32
Potentials of Cellular Reprogramming as a Novel Strategy for Neuroregeneration
Fang, L., Wazan, L. E., Tan, C. L. H., Nguyen, T., Hung, S. S. C., Hewitt, A. W., & Wong, R. C. B. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00460 · Cited by 31
“Since then, two follow-up studies have confirmed this finding and improved the reprogramming method, by using AAVmediated CRISPR/Cas9 to knockout Nrl and preserve cone functions in multiple mouse models of photoreceptor degeneration (Yu et al., 2017; Zhu et al., 2017).”
BackgroundTargeting of the NRL Pathway as a Therapeutic Strategy to Treat Retinitis Pigmentosa
Moore, S. M., Skowronska‐Krawczyk, D., & Chao, D. L. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072224 · Cited by 31
“Finally, CRISPR/Cas9 NRL knockout at P14 in the RhoP347S rod degeneration model significantly slowed light-adapted b-wave ERG degeneration over time and protected photoreceptors from apoptosis [76].”
BackgroundMethodInfluentialGeneration of Cashmere Goats Carrying an EDAR Gene Mutant Using CRISPR-Cas9-Mediated Genome Editing
Hao, F., Yan, W., Li, X., Wang, H., Wang, Y., Hu, X., Liu, X., Liang, H., & Liu, D. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.23890 · Cited by 32
“Owing to its efficiency and advantages in terms of specificity, the CRISPR–Cas9 system has been widely used to edit genes in several species and examine gene functions in model organisms [21-26].”
BackgroundInherited Eye Diseases with Retinal Manifestations through the Eyes of Homeobox Genes
Markitantova, Y. V., & Simirskii, V. N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051602 · Cited by 33
“As a result, at first there was a significant decrease in Nrl expression, and then downregulation of rod genes and upregulation of cone cells, as well as inhibition of the death of cone cells [9].”
BackgroundGene Therapy for Inherited Retinal Degeneration
Arbabi, A., Liu, A., & Ameri, H. (2019) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2018.0087 · Cited by 30
“183 Disruption of the Nrl gene in rod photoreceptors with AAV-delivered CRISPR/Cas9 was shown to prevent retinal degeneration in mice with RP. 180 In another study, dual AAVs were used, primarily to disrupt the endogenous Rho gene using CRISPR/Cas9 in a mutation-independent manner, then inserted…”
Non-viral nanocarriers for CRISPR-Cas9 gene editing system delivery
Tang, X., Wang, Z., Zhang, Y., Mu, W., & Han, X. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.135116 · Cited by 31
Engineered CRISPR Systems for Next Generation Gene Therapies
Pineda, M., Moghadam, F., Ebrahimkhani, M. R., & Kiani, S. (2017) · ACS Synthetic Biology · doi:10.1021/acssynbio.7b00011 · Cited by 32
Botto, C., Dalkara, D., & El-Amraoui, A. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.737632 · Cited by 32
“This approach is based on repression of the Nrl gene, which can lead to the in situ reprogramming of rods cells into cone-like cells resistant to RP-specific mutations (Yu et al., 2017; Moreno et al., 2018).”
BackgroundCRISPRedict: a CRISPR-Cas9 web tool for interpretable efficiency predictions
Konstantakos, V., Nentidis, A., Krithara, A., & Παλιούρας, Γ. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac466 · Cited by 33
“(21) attempted to knockdown the Nrl gene to prevent retinal degeneration in a mouse model and sug-”
BackgroundSpliceosome-Mediated Pre-mRNA trans-Splicing Can Repair CEP290 mRNA
Dooley, S. J., McDougald, D. S., Fisher, K. J., Bennicelli, J. L., Mitchell, L. G., & Bennett, J. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.05.014 · Cited by 32
A New Generation of Gene Therapies as the Future of Wet AMD Treatment
Błasiak, J., Pawłowska, E., Ciupińska, J., Derwich, M., Szczepańska, J., & Kaarniranta, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042386 · Cited by 33
“That is why some modifications to the classical CRISPR-Cas system have been successfully introduced in the treatment of inherited retina diseases [67–73].”
BackgroundA Drug-Tunable Gene Therapy for Broad-Spectrum Protection against Retinal Degeneration
Santiago, C. P., Keuthan, C. J., Boye, S. L., Boye, S. L., Imam, A. A., & Ash, J. D. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.07.016 · Cited by 31
New Therapeutics for Extracellular Vesicles: Delivering CRISPR for Cancer Treatment
Yan, B., & Liang, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415758 · Cited by 28
“Finally, the AAVCRISPR disrupted the Nrl gene and rescued the retinal degeneration [61].”
BackgroundGene editing prospects for treating inherited retinal diseases
Benati, D., Patrizi, C., & Recchia, A. (2019) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2019-106473 · Cited by 30
Potential therapeutic strategies for photoreceptor degeneration: the path to restore vision
Karamali, F., Behtaj, S., Abraki, S. B., Hadady, H., Atefi, A., Savoj, S., Soroushzadeh, S., Najafian, S., Nasr‐Esfahani, M. H., & Klassen, H. J. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03738-4 · Cited by 27
“The results showed that CRISPR/Cas9-mediated Nrl disruption improves rod survival, consequently preventing secondary cone degeneration [372].”
BackgroundBasic Principles and Clinical Applications of CRISPR-Based Genome Editing
Lim, J. M., & Kim, S. (2022) · Yonsei Medical Journal · doi:10.3349/ymj.2022.63.2.105 · Cited by 28
Carrella, S., Guida, M. D., Brillante, S., Piccolo, D., Ciampi, L., Guadagnino, I., García‐Piqueras, J., Pizzo, M., Marrocco, E., Molinari, M., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202215941 · Cited by 28
“P347S animals displayed a dramatic impairment of OKR response, in agreement with previous reports (Yu et al , 2017).”
Prdm1 overexpression causes a photoreceptor fate-shift in nascent, but not mature, bipolar cells
Goodson, N., Park, K. U., Silver, J. S., Chiodo, V. A., Hauswirth, W. W., & Brzezinski, J. A. (2020) · Developmental Biology · doi:10.1016/j.ydbio.2020.06.003 · Cited by 26
“Removing Nrl shortly after birth incompletely converts rods into cones, while targeting Nrl in the adult retina has a more modest effect that is limited to changes in rod- and cone-specific gene expression (Montana et al., 2013; Yu et al., 2017; Zhu et al., 2017).”
BackgroundFuentes, C., & Schaffer, D. V. (2018) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2018.08.003 · Cited by 28
New Editing Tools for Gene Therapy in Inherited Retinal Dystrophies
Pulman, J., Sahel, J.-A., & Dalkara, D. (2022) · The CRISPR Journal · doi:10.1089/crispr.2021.0141 · Cited by 23
CRISPR Editing Technology in Biological and Biomedical Investigation
White, M. K., Kaminski, R., Young, W., Roehm, P. C., & Khalili, K. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26099 · Cited by 27
“…mouse models of retinal degeneration exhibited considerable improvement in rod survival and cone function in response to treatment, suggesting that CRISPR-mediated disruption of NRL in rods may be a promising potential therapeutic option for retinitis pigmentosa patients [Yu et al., 2017].”
BackgroundUtility of Self-Destructing CRISPR/Cas Constructs for Targeted Gene Editing in the Retina
Li, F., Hung, S. S. C., Mohd Khalid, M. K. N., Wang, J.-H., Chrysostomou, V., Wong, V. H. Y., Singh, V., Wing, K., Tu, L., Bender, J. A., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.021 · Cited by 24
“More recently, Yu et al. 10 demonstrated that CRISPR/Cas9-mediated disruption of a neural retina-specific leucine zipper protein ( NRL ) sig-nificantly improved rod survival and preserved cone function in a murine model of retinal degeneration.”
CRISPR-Based Genome Editing as a New Therapeutic Tool in Retinal Diseases
Rasoulinejad, S. A., & Maroufi, F. (2021) · Molecular Biotechnology · doi:10.1007/s12033-021-00345-4 · Cited by 26
Are Tanycytes the Missing Link Between Type 2 Diabetes and Alzheimer’s Disease?
Raikwar, S. P., Bhagavan, S., Ramaswamy, S. B., Thangavel, R., Dubova, I., Selvakumar, G. P., Ahmed, M. E., Kempuraj, D., Zaheer, S. A., Iyer, S. S., et al. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1123-8 · Cited by 25
The evolution of microglia replacement: A new paradigm for CNS disease therapy
Rao, Y., Bai, Y., Li, X., Du, B., & Peng, B. (2025) · Cell stem cell · doi:10.1016/j.stem.2025.10.014 · Cited by 27
Therapeutic application of the CRISPR system: current issues and new prospects
Lee, M., & Kim, S. (2019) · Human Genetics · doi:10.1007/s00439-019-02028-2 · Cited by 25
Understanding the Potential of Genome Editing in Parkinson’s Disease
Arango, D., Bittar, A., Esmeral, N. P., Ocasión, C., Muñoz-Camargo, C., Cruz, J. C., Reyes, L. H., & Bloch, N. I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179241 · Cited by 26
“Since designing a single plasmid vector with all the CRISPR components can be challenging, promising results have been obtained using separate plasmids with the nuclease and sgRNA sequences [161,162].”
BackgroundThe Application of CRISPR/Cas9 for the Treatment of Retinal Diseases.
Peddle, C. F., & MacLaren, R. E. (2017) · PubMed Central · Cited by 33
Rathod, R. J., Surendran, H., Battu, R., Desai, J., & Pal, R. (2018) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2018.02.002 · Cited by 22
Translation of CRISPR Genome Surgery to the Bedside for Retinal Diseases
Xu, C. L., Cho, G. Y., Sengillo, J. D., Park, K. S., Mahajan, V. B., & Tsang, S. H. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00046 · Cited by 19
“…in the retina include disease model generation (Zhong et al., 2015; Arno et al., 2016; Collery et al., 2016) and expanded understanding of disease mechanism (Bassuk et al., 2016; Latella et al., 2016; Yiu et al., 2016; Dong et al., 2017; Kim et al., 2017; Ruan et al., 2017; Yu et al., 2017).”
BackgroundCarvalho, C., Lemos, L., Antas, P., & Seabra, M. C. (2023) · Frontiers in Ophthalmology · doi:10.3389/fopht.2023.1270561 · Cited by 21
“Another interesting concept that has been proposed is to employ NHEJ-mediated genome editing to reprogram affected cell populations into functionally related cell types that are resistant to disease-causing mutations (24, 25).”
BackgroundHuman eye conditions: insights from the fly eye
Gaspar, P., Almudí, I., Nunes, M. D. S., & McGregor, A. P. (2018) · Human Genetics · doi:10.1007/s00439-018-1948-2 · Cited by 23
Oel, A. P., Neil, G. J., Dong, E. M., Balay, S. D., Collett, K., & Allison, W. T. (2020) · iScience · doi:10.1016/j.isci.2020.101805 · Cited by 24
“The tiger salamander has evolved a second type of rod, the so-called green rod, which expresses Sws2 opsin and is sensitive to blue light (Isayama et al., 2014; Mariani, 1986; Zhang and Wu, 2009), although these salamanders retain a dedicated Sws2-expressing cone as well.”
BackgroundThe pigmented epithelium, a bright partner against photoreceptor degeneration
Letelier, J., Bovolenta, P., & Martínez‐Morales, J. R. (2017) · Journal of Neurogenetics · doi:10.1080/01677063.2017.1395876 · Cited by 30
“After injection, cone function was preserved in all models opening the possibility to use this strategy for gene therapy (Yu et al., 2017).”
BackgroundInfluentialUse of AAV Vectors for CRISPR-Mediated In Vivo Genome Editing in the Retina
Yu, W., & Wu, Z. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9139-6_7 · Cited by 20
Self-citationGenome editing and kidney health
Tavakolidakhrabadi, N., Aulicino, F., May, C., Saleem, M. A., Berger, I., & Welsh, G. I. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae119 · Cited by 21
“So far, local and systemic administration of AAV vectors encoding CRISPR and gRNA have been studied for gene correction in different diseases, including post-mitotic retina [29 , 69 ], Duchenne muscular dystrophy [70 ] and Huntington’s disease [71 ].”
BackgroundCherif, K., Gérard, C., Rousseau, J., Ouellet, D. L., Chapdelaine, P., & Tremblay, J. P. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.04.009 · Cited by 19
Blossom of CRISPR technologies and applications in disease treatment
Liu, H., Wang, L., & Luo, Y. (2018) · Synthetic and Systems Biotechnology · doi:10.1016/j.synbio.2018.10.003 · Cited by 21
“cine zipper protein gene (Nrl gene) could also be prevented [160].”
BackgroundCreating an Ocular Biofactory: Surgical Approaches in Gene Therapy for Acquired Retinal Diseases
Xu, D. N., Khan, M., & Ho, A. C. (2021) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000362 · Cited by 19
Clinical trials and promising preclinical applications of CRISPR/Cas gene editing
Çerçi, B., Uzay, İ. A., Kara, M. K., & Dinçer, P. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121204 · Cited by 22
Targeting and silencing of rhodopsin by ectopic expression of the transcription factor KLF15
Botta, S., de Prisco, N., Marrocco, E., Renda, M., Sofia, M., Curion, F., Bacci, M. L., Ventrella, D., Wilson, C., Gesualdo, C., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.96560 · Cited by 18
Han, H., Huang, W., Du, W., Shen, Q., Yang, Z., Li, M. D., & Chang, S. L. (2019) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-019-09845-2 · Cited by 20
“generated neural retina leucine zipper (Nrl) knockdown mice by adenoassociated virus-delivered CRISPR/Cas9 (Yu et al. 2017).”
BackgroundMethodCurrent and future therapeutic strategies for the treatment of retinal neurodegenerative diseases
Cuenca, N., Maneu, V., & Lax, P. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.314305 · Cited by 18
“In this sense, CRISP/Cas editing tools used to amend genetic missenses, need to fix secondary effects, as those related to the immune response (Yu et al., 2017); stem cell approaches have to procure the functionality of transplanted cells in the recipient, to assure the accurate establishment of…”
Banda, A., Impomeni, O., Singh, A., Baloch, A. R., Hu, W., & Jaijyan, D. K. (2024) · Vaccines · doi:10.3390/vaccines12060636 · Cited by 17
“…disease [144], Huntington’s disease [145], Parkinson’s disease [146], Tyrosinemia [147], Duchenne muscular dystrophy [148], Tay–Sachs disease [149], Fragile X syndrome [150], phenylketonuria [150], blind-Vaccines ness [151], cataracts [152], cancer [153], blood disorders [154], and others.”
BackgroundA Ketogenic & Low-Protein Diet Slows Retinal Degeneration in rd10 Mice
Ryals, R. C., Huang, S. J., Wafai, D., Bernert, C., Steele, W., Six, M., Bonthala, S., Titus, H. E., Yang, P. G., Gillingham, M. B., et al. (2020) · Translational Vision Science & Technology · doi:10.1167/tvst.9.11.18 · Cited by 16
“47 Additionally, reduced rates of rhodopsin regeneration and/or reduced rhodopsin protein led to protection against light-induced retinopathy.”
Genetics and therapy for pediatric eye diseases
Chen, H. Y., Lehmann, O. J., & Swaroop, A. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103360 · Cited by 17
“survival of (dysfunctional) rod photoreceptors while preserving the cones that are essential for the macula and thus fine vision [62].”
BackgroundSelf-citationSupramolecular Nanosubstrate‐Mediated Delivery for CRISPR/Cas9 Gene Disruption and Deletion
Ban, Q., Yang, P., Chou, S., Qiao, L., Xia, H., Xue, J., Wang, F., Xu, X., Sun, N., Zhang, R. Y., et al. (2021) · Small · doi:10.1002/smll.202100546 · Cited by 17
Unraveling the multiplex folding of nucleosome chains in higher order chromatin
Grigoryev, S. A., & Schubert, M. (2019) · Essays in Biochemistry · doi:10.1042/ebc20180066 · Cited by 15
Pasquini, G., Cora, V., Swiersy, A., Achberger, K., Antkowiak, L., Müller, B., Wimmer, T., Fraschka, S. A. K., Casadei, N., Ueffing, M., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041380 · Cited by 16
“There have been some studies demonstrating that it is possible to knock down protein expression via NHEJ in adult photoreceptors (PR) cells [20].”
BackgroundChuang, K., Ma, F., & Priore, L. V. D. (2017) · PubMed Central · Cited by 15
CRISPR GENOME SURGERY IN THE RETINA IN LIGHT OF OFF-TARGETING
Cho, G. Y., Schaefer, K. A., Bassuk, A. G., Tsang, S. H., & Mahajan, V. B. (2018) · Retina · doi:10.1097/iae.0000000000002197 · Cited by 16
CRISPR/Cas9 genome surgery for retinal diseases
Xu, C. L., Park, K. S., & Tsang, S. H. (2018) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2018.05.001 · Cited by 14
Mutation-independent therapies for retinal diseases: focus on gene-based approaches
Carrella, S., Indrieri, A., Franco, B., & Banfi, S. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.588234 · Cited by 14
“CRISPR/Cas9-mediated Nrl loss showed an improvement of photoreceptors survival and function (Yu et al., 2017).”
BackgroundChronic In Vivo CRISPR-Cas Genome Editing: Challenges, Long-Term Safety, and Outlook
Bao, C., Channell, C. I., Tseng, Y.-H., Bailey, J., Sbaiti, N., Demirkol, A., & Tsang, S. H. (2026) · Cells · doi:10.3390/cells15020156 · Cited by 18
“Another study found that knockdown of the Nrl gene in vivo was also able to rescue retinal degeneration in Rho P347S mice with no observed off-target mutations at 10 genomic loci when followed for 9.5 months [111].”
InfluentialCRISPR/Cas9: an overview of recent developments and applications in cancer research
Devi, S. N., Rana, R., Malik, P., & Ganguly, N. K. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001081 · Cited by 17
“Therefore, viral and nonviral delivery methods, such as AAV, have been developed for gene therapy due to their compatibility with most human populations and high transduction ef fi ciency [112 – 115] and can be apply directly to the target organ or can apply systemically [115 – 118] .”
BackgroundAn introduction to genome editing CRISPR-Cas systems
Singh, V. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818140-9.00001-5 · Cited by 18
CRISPR/Cas systems usher in a new era of disease treatment and diagnosis
Li, R., Wang, Q., She, K., Lu, F., & Yang, Y. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00095-y · Cited by 14
Kim, S., Jeong, Y. K., Cho, C. S., Lee, S., Sohn, C. H., Kim, J. H., Jeong, Y., Jo, D. H., Bae, S., & Lee, H. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202201825 · Cited by 14
Self-citationLu, Z., Wang, F., Xia, Y., Cheng, S., Zhang, J., Qin, X., Tian, X., Wang, B., Qiu, J., Zou, Z., et al. (2022) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2022.114370 · Cited by 13
Therapeutic landscape for inherited ocular diseases: current and emerging therapies
Chan, H. W., Oh, J., & Leroy, B. P. (2023) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2022-179 · Cited by 13
“Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 is a forefront gene editing technology involving a guiding RNA (gRNA) and a nuclease (genomic scissors) such as Cas9.[63] The CRISPR/Cas9 complex binds, cleaves and removes the target mutated gene, while a separate AAV vector simultaneously delive…”
BackgroundProtective effects of patchouli alcohol against DSS-induced ulcerative colitis
Han, H., Gao, M., Wang, F., Luo, Z., Jiang, X., Qiu, Y., Su, J., Duan, X., Luo, S., Tang, S., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-66259-8 · Cited by 16
“TBO staining was executed as previously described 31 .”
Lin, B., & Youdim, M. B. H. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.07.031 · Cited by 13
Application of CRISPR-Cas9 in eye disease
Wu, W., Tang, L., D'Amore, P. A., & Lei, H. (2017) · Experimental Eye Research · doi:10.1016/j.exer.2017.06.007 · Cited by 16
Determining Photoreceptor Cell Identity: Rod Versus Cone Fate Governed by tbx2b Opposing nrl
Neil, G. J., Kluttig, K. H., & Allison, W. T. (2024) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.65.1.39 · Cited by 12
“Considering the use of Nrl − / − mutant mice as “cone-rich” ophthalmology models, the potential of NRL as a gene therapy target, 29 and NRL ’s importance in the study of photoreceptor specification, the elucidation of the role of tbx2b in rod versus cone development is an exciting opportunity to…”
Hu, J., Yi, S., Wang, C., Zhang, Y., Tang, J., Huang, X., Yang, L., Yang, J., & Li, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.603939 · Cited by 12
“Vector genome of AAV2/DJ-GFP and AAV2/DJ-TNFAIP3 (10(8) copies; Hanbio, Shanghai, China) were injected into the subretinal cavity of mouse eyes as published previously (Figure S1B) (39).”
MethodClinical applications of retinal gene therapies
Fu, X., Huu, V. A. N., Duan, Y., Kermany, D., Valentim, C. C. S., Zhang, R., Zhu, J., Zhang, C. L., Sun, X., & Zhang, K. (2018) · Precision Clinical Medicine · doi:10.1093/pcmedi/pby004 · Cited by 13
“5).(188,189) These results indicate that therapeutic cellular reprogramming can serve as a novel treatment approach that is gene- and mutationindependent, broadening implications for genetic disease therapy.”
BackgroundSelf-citationŽužić, M., Striebel, J., Pawlick, J. S., Sharma, K., Holz, F. G., & Busskamp, V. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2022.101065 · Cited by 13
“nation with AAV-mediated gene delivery (Yu et al., 2017).”
Campla, C. K., Mast, H., Dong, L., Lei, J., Halford, S., Sekaran, S., & Swaroop, A. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy388 · Cited by 15
Self-citationGenome Editing in Retinal Diseases using CRISPR Technology
Yiu, G. C. (2017) · Ophthalmology Retina · doi:10.1016/j.oret.2017.09.015 · Cited by 12
Shining light on CRISPR/Cas9 therapeutics for inherited retinal diseases
Geiger, A., Kennedy, J. G., Staker, L. G., Wensel, T. G., Casson, R. J., & Thomas, P. Q. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101376 · Cited by 11
Losing, preserving, and restoring vision from neurodegeneration in the eye
Kerschensteiner, D. (2023) · Current Biology · doi:10.1016/j.cub.2023.08.044 · Cited by 12
“Transdifferentiation preserves vision in RP mouse models because cods produce RdCVF and, thus, support the cones 209,210 .”
BackgroundKulbay, M., Tuli, N., Akdag, A., Ali, S. K., & Qian, C. X. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13144224 · Cited by 13
“In another non-viral approach, empty virus-like particles (eVLPs) were used to deliver ABE RNPs to the RPE cells of rd12 mice, targeting the Rpe65 gene by subretinal injection (ABE7.”
MethodNeuronal Reprogramming for Tissue Repair and Neuroregeneration
Liou, R. H.-C., Edwards, T. L., Martin, K. R. G., & Wong, R. C. B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124273 · Cited by 11
“A subsequent study further showed that this strategy can improve visual responses in three different retinal degenerative models [140].”
BackgroundYang, D., Wu, X., Zhou, Y., Wang, W., & Wang, Z. (2020) · EMBO Reports · doi:10.15252/embr.201949431 · Cited by 12
“The optimal knockdown effect of CRISPR/Cas9 induced by in vivo AAV injection requires 6 – 8 weeks (Appendix Fig S3B and C) (Long et al , 2016; Yang et al , 2016; Yu et al , 2017).”
CRISPR-Cas9 based genome editing for defective gene correction in humans and other mammals
Karapurkar, J. K., Antao, A. M., Kim, K.-S., & Ramakrishna, S. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.01.018 · Cited by 14
CRISPR Cas9 based genome editing in inherited retinal dystrophies
Bansal, M., Acharya, S., Sharma, S., Phutela, R., Rauthan, R., Maiti, S., & Chakraborty, D. (2021) · Ophthalmic Genetics · doi:10.1080/13816810.2021.1904421 · Cited by 12
“Wherein, NRL gene knockdown using CRISPR, was found to change rod morphology to cones, thereby protecting the photoreceptors from RP damaging genes (41).”
BackgroundChang, A. Y. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2651-1_33 · Cited by 20
Fuster‐García, C., García‐Bohórquez, B., Rodríguez‐Muñoz, A., Millán, J. M., & García‐García, G. (2020) · Genes · doi:10.3390/genes11050473 · Cited by 12
“arRP/adRP Nrl Undetermined KO AAV transduction (subretinal injection) SpCas9 [75]”
BackgroundInfluentialGenome editing: the breakthrough technology for inherited retinal disease?
Smith, A. J., Carter, S. P., & Kennedy, B. N. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1347629 · Cited by 11
Frontiers of CRISPR-Cas9 for Cancer Research and Therapy
Banerjee, A., Malonia, S. K., & Dutta, S. (2021) · Journal of Exploratory Research in Pharmacology · doi:10.14218/jerp.2020.00033 · Cited by 11
Barwick, S. R., Xiao, H., WOLFF, D. A., Wang, J., Perry, E., Marshall, B., & Smith, S. B. (2023) · Experimental Eye Research · doi:10.1016/j.exer.2023.109462 · Cited by 9
Autosomal dominant retinitis pigmentosa with toxic gain of function: Mechanisms and therapeutics
Narasimhan, I., Murali, A., Krishnakumar, S., Ramalingam, S., & Parameswaran, S. (2020) · European Journal of Ophthalmology · doi:10.1177/1120672120957605 · Cited by 9
Zheng, Q., Wang, W., Zhou, Y., Mo, J., Chang, X., Zha, Z., & Zha, L. (2023) · Biomaterials Science · doi:10.1039/d3bm00788j · Cited by 12
Specific photoreceptor cell fate pathways are differentially altered in NR2E3-associated diseases
Aísa-Marín, I., Rovira, Q., Díaz, N., Calvo‐López, L., Vaquerizas, J. M., & Marfany, G. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106463 · Cited by 9
Mittal, R., Bencie, N., Parrish, J. M., Liu, G. E., Mittal, J., Yan, D. L. S., & Liu, X. Z. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00009 · Cited by 9
“As a proof of this concept, CRISPR/Cas9 genome editing has been demonstrated to produce substantial improvement in mice with regard to retinal cone function and rod survival via the NRL gene (Peng et al., 2017; Yu et al., 2017).”
BackgroundCzajka, M., Zajkowska, A., Gawlak, M., Bujalska‐Zadrożny, M., & Małecki, M. (2020) · Anticancer Research · doi:10.21873/anticanres.14448 · Cited by 9
Promoter Orientation within an AAV-CRISPR Vector Affects Cas9 Expression and Gene Editing Efficiency
Fry, L. E., Peddle, C. F., Stevanovic, M., Barnard, A. R., McClements, M. E., & MacLaren, R. E. (2020) · The CRISPR Journal · doi:10.1089/crispr.2020.0021 · Cited by 11
Toward In Vivo Gene Therapy Using CRISPR
Skipper, K. A., & Mikkelsen, J. G. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9170-9_18 · Cited by 8
CRISPR/Cas9 in cancer: An attempt to the present trends and future prospects
Kaligotla, V. S. A., Jasti, T., & Kandra, P. (2021) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2200 · Cited by 9
Polymeric Micelles for Targeted Drug Delivery Systems
Guliy, O. I., Fomin, A. S., Григорьевна, Ж. Е., Kozlov, S., Staroverov, S. A., & Dykman, L. A. (2022) · Nanotechnology in the life sciences · doi:10.1007/978-3-031-12658-1_18 · Cited by 15
Kolesnikov, A. V., Murphy, D. P., Corbo, J. C., & Kefalov, V. J. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2316118121 · Cited by 8
“Such a strategy was used previously to knock out mouse Nrl, thereby delaying degeneration in multiple mouse models of RP (9, 11).”
BackgroundMethod
Metadata
- Authors
- Yu, W., Mookherjee, S., Chaitankar, V., Hiriyanna, S., Kim, J.-W., Brooks, M., Ataeijannati, Y., Sun, X., Dong, L., Li, T., Swaroop, A., & Wu, Z.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Wu, Zhijian
- ORCID
- Venue
- Nature Communications
- Published
- 2017-03-14
- Volume
- 8
- Issue
- 1
- Pages
- 14716-14716
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC5355895
- OpenAlex
- W2620315774
- Cited by
- 271
- References
- 70
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 23 · 2023: 21 · 2022: 35 · 2021: 41 · 2020: 38 · 2019: 24 · 2018: 51 · 2017: 20
- FWCI
- 14.86
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health
- National Eye Institute
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- retinitis pigmentosa, CRISPR/Cas9 genome editing, AAV gene delivery, rod photoreceptors, cone photoreceptors, retinal degeneration, gene therapy, mouse model
- MeSH terms
- Gene Editing, Dependovirus, Animals, Cell Survival, Eye Proteins, Retinal Degeneration, Retinitis Pigmentosa, Retinal Rod Photoreceptor Cells, Retinal Cone Photoreceptor Cells, Basic-Leucine Zipper Transcription Factors, Mice, Gene Knockdown Techniques, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.